We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Solicitor Says U.S. Supreme Court Should Deny Petition In Patent, Antitrust Case

(October 13, 2016, 5:44 PM EDT) -- WASHINGTON, D.C. — A petition by drug manufacturers asking the U.S. Supreme Court to consider “whether a reverse-payment agreement is immune from antitrust scrutiny if the consideration given by the brand-name manufacturer to the generic challenger is not a cash payment, but rather a promise to restrict its competition with the challenger after the challenger enters the market” should be denied, the U.S. solicitor general says in an Oct. 3 amicus curiae brief (SmithKline Beecham Corp., et al. v. King Drug Company of Florence Inc., No....
To view the full article, register now.